Psychedelic-Assisted Therapy in 2026: What's Legal, What's Coming

psychedelic therapyketaminepsilocybinmental health2026

The phrase “psychedelic-assisted therapy” covers a wide range of substances and settings — from a licensed ketamine infusion center in your city to an FDA clinical trial at a major research hospital. In 2026, the legal and regulatory picture is clearer than it was just a few years ago, but it still requires careful navigation. This post explains what’s available today, what’s still in the pipeline, and how to think about the difference.

Only one psychedelic compound has FDA approval for a psychiatric indication: esketamine (Spravato), a nasal spray form of ketamine. The FDA approved Spravato in 2019 for treatment-resistant depression (TRD) and in 2020 for major depressive disorder with acute suicidal ideation or behavior. It is a Schedule III controlled substance and must be administered in a certified healthcare setting under direct supervision — patients cannot take it home.

Racemic ketamine (the IV or IM form most clinics use) is a Schedule III substance approved as an anesthetic since the 1970s. When a psychiatrist or anesthesiologist uses it for depression or PTSD, they are prescribing it off-label, which is both legal and common in medical practice. The relevant CPT billing codes for ketamine-related services include 99213 (office visit), 90791 (psychiatric evaluation), and J3490 (unclassified drug injection, often used for off-label IV ketamine). ICD-10 codes that frequently appear in ketamine care documentation include F32.9 (major depressive disorder, single episode, unspecified) and F33.2 (major depressive disorder, recurrent, severe without psychotic features).

Oregon became the first US state to regulate psilocybin services for adults under Measure 109, with licensed service centers operating since 2023. Colorado’s Proposition 122 followed, creating a regulated framework for psilocybin and several other psychedelics. These programs allow supervised use in licensed settings — they are not medical prescriptions and do not involve a diagnosis or treatment plan in the clinical sense.

Outside those state frameworks, psilocybin, MDMA, LSD, and DMT remain Schedule I at the federal level, meaning they have no currently accepted medical use under federal law. Clinical trials are a legal pathway to access those compounds under research protocols, but not as standalone treatments.

Where Ketamine Fits

For most people exploring psychedelic-assisted therapy today, ketamine is the practical legal entry point. It is the only option available through a conventional clinic visit without enrollment in a research study. Many clinics describe their approach as “ketamine-assisted psychotherapy” — pairing infusions with integration sessions billed under 90837 (psychotherapy, 60 min) with a licensed therapist.

If you or a family member is considering this path, it is worth understanding that not all ketamine clinics offer the same level of care. Some focus on standalone infusions; others integrate preparation and integration therapy into the program. The questions worth asking any clinic include: Who supervises the infusions? Is a psychiatrist involved in the evaluation? What does the integration support look like after the series ends?

We are not in a position to recommend specific clinics or tell you whether ketamine is appropriate for your situation — only a licensed clinician can do that. What we can say is that verifying a provider’s credentials through the NPPES NPI registry is a reasonable starting point.

MDMA and Psilocybin: Still Pending

The most widely anticipated FDA approval in the psychedelic space has been MDMA-assisted therapy for PTSD, developed primarily by MAPS (Multidisciplinary Association for Psychedelic Studies). The FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics in August 2024, requesting an additional Phase 3 trial before approval. That trial is ongoing. The timeline for resubmission and approval review extends into 2026 and likely beyond.

Psilocybin for depression has multiple active FDA Breakthrough Therapy designations. Compass Pathways and Usona Institute are among the sponsors running Phase 2 and Phase 3 trials. Several academic medical centers are active study sites. Enrollment in these trials is generally available to people who meet specific criteria — asking your psychiatrist whether you qualify is a reasonable step if you are interested.

The FDA does not currently have a timeline to approve psilocybin as a prescription therapy, and no approval should be assumed before a New Drug Application is reviewed and accepted. For current trial information, ClinicalTrials.gov lists all active studies.

What Patients Should Realistically Expect

If you are researching psychedelic-assisted therapy for yourself or a loved one, the most useful frame is to distinguish between what is available now and what may be available in the future. Today, the realistic options are:

  • Spravato at an REMS-certified clinic if you have treatment-resistant depression and insurance coverage or the means to pay out of pocket
  • Off-label IV or IM ketamine at a licensed clinic, typically self-pay
  • Oregon or Colorado psilocybin services if you are an adult and can travel to a licensed center
  • Clinical trial enrollment for MDMA, psilocybin, or other compounds if you meet eligibility criteria

The regulatory landscape will continue to evolve. Staying connected with credible sources — including NIMH and SAMHSA — is a reasonable way to track changes that may affect your options.

Reach out if you’d like to connect with a provider in your area.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.